167 related articles for article (PubMed ID: 16611652)
1. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study.
Hughes RJ; Jais X; Bonderman D; Suntharalingam J; Humbert M; Lang I; Simonneau G; Pepke-Zaba J
Eur Respir J; 2006 Jul; 28(1):138-43. PubMed ID: 16611652
[TBL] [Abstract][Full Text] [Related]
2. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
3. Bosentan for chronic thromboembolic pulmonary hypertension.
Confalonieri M; Kodric M; Longo C; Vassallo FG
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
[TBL] [Abstract][Full Text] [Related]
4. Bosentan for patients with chronic thromboembolic pulmonary hypertension.
Vassallo FG; Kodric M; Scarduelli C; Harari S; Potena A; Scarda A; Piattella M; Cassandro R; Confalonieri M
Eur J Intern Med; 2009 Jan; 20(1):24-9. PubMed ID: 19237088
[TBL] [Abstract][Full Text] [Related]
5. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
Reesink HJ; Surie S; Kloek JJ; Tan HL; Tepaske R; Fedullo PF; Bresser P
J Thorac Cardiovasc Surg; 2010 Jan; 139(1):85-91. PubMed ID: 19660388
[TBL] [Abstract][Full Text] [Related]
6. Long-term bosentan in chronic thromboembolic pulmonary hypertension.
Seyfarth HJ; Hammerschmidt S; Pankau H; Winkler J; Wirtz H
Respiration; 2007; 74(3):287-92. PubMed ID: 16699254
[TBL] [Abstract][Full Text] [Related]
7. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
Bonderman D; Nowotny R; Skoro-Sajer N; Jakowitsch J; Adlbrecht C; Klepetko W; Lang IM
Chest; 2005 Oct; 128(4):2599-603. PubMed ID: 16236930
[TBL] [Abstract][Full Text] [Related]
8. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
9. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Ghofrani HA; Hoeper MM; Halank M; Meyer FJ; Staehler G; Behr J; Ewert R; Weimann G; Grimminger F
Eur Respir J; 2010 Oct; 36(4):792-9. PubMed ID: 20530034
[TBL] [Abstract][Full Text] [Related]
10. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
Hoeper MM; Kramm T; Wilkens H; Schulze C; Schäfers HJ; Welte T; Mayer E
Chest; 2005 Oct; 128(4):2363-7. PubMed ID: 16236895
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.
Degano B; Yaïci A; Le Pavec J; Savale L; Jaïs X; Camara B; Humbert M; Simonneau G; Sitbon O
Eur Respir J; 2009 Jan; 33(1):92-8. PubMed ID: 18799506
[TBL] [Abstract][Full Text] [Related]
12. Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2.
Hirashiki A; Adachi S; Nakano Y; Kono Y; Shimazu S; Shimizu S; Morimoto R; Okumura T; Takeshita K; Yamada S; Murohara T; Kondo T
Life Sci; 2014 Nov; 118(2):397-403. PubMed ID: 24641953
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
[TBL] [Abstract][Full Text] [Related]
14. Chronic thromboembolic pulmonary hypertension: role of medical therapy.
Pepke-Zaba J; Jansa P; Kim NH; Naeije R; Simonneau G
Eur Respir J; 2013 Apr; 41(4):985-90. PubMed ID: 23397304
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
Durongpisitkul K; Jakrapanichakul D; Sompradikul S
J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
[TBL] [Abstract][Full Text] [Related]
16. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
17. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
[TBL] [Abstract][Full Text] [Related]
18. Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options.
Lang IM
Eur Respir Rev; 2009 Mar; 18(111):24-8. PubMed ID: 20956119
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
[TBL] [Abstract][Full Text] [Related]
20. Bosentan therapy for portopulmonary hypertension.
Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]